HTGF invests in CollimateHealth's seed round of over 6 million euros
The company is developing a microbeam therapy to activate the immune system against cancer and plans first patients by 2028.
See the latest news and media coverage for HTGF. We track all announcements, press releases, and industry mentions in real time, all in one place.
Early-stage technology venture capital investor
htgf.deLast updated
In short: HTGF achieved its most significant exit ever with the sale of Tubulis to Gilead Sciences for up to $5 billion and expanded its deep-tech portfolio.
The company is developing a microbeam therapy to activate the immune system against cancer and plans first patients by 2028.
It publishes a playbook to address Germany's capital allocation gap in venture capital.
The acquisition accelerates in vivo CAR-T clinical translation, combining transposon and LNP technologies.
The US authority approved the drug as the first therapy against hepatitis delta. Gilead Sciences took over the development.
Tacalyx Secures €11 Million to Advance Lead TACA-Targeting ADC Programme Toward the ClinicBerlin, Germany, April 29, 2026 (GLOBE NEWSWIRE) ...
Image credit: HTGF. The federal government is strategically realigning the financing of technology start-ups and scale-ups. In future, the DeepTech & Climate Fund (DTCF) shall be under the roof...
The German Federal Government plans to consolidate and strengthen financing for technology startups and scaleups.
The Dutch biochemistry company Mevaldi B.V. has completed a financing round with the High-Tech Gründerfonds (HTGF) and ICIG Ventures, the venture capital unit of the International Chemical I...
Track HTGF and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to HTGF and other trending companies.